HistoGeneX

Official Twitter account of HistoGeneX Laboratories. Watch for updates about how our global laboratory system is bettering the lives of patients facing cancer.

[HistoGeneX @HistoGeneX]

Excited to be at #AACR2018! Discover new CTC solutions from HistoGeneX and RareCyte. Booth #3252. We have completed validation of this platform at our global labs and are now using it for clinical trials.

[HistoGeneX @HistoGeneX]

Pleased to announce the results of a study in collaboration with @Bartscancer @QMUniversity #London and @HistoGeneX pathologists were published in @NatureMedicine https://t.co/Yb7kpF50vr
#TissuePathology #ImmunoOncology #HistoGeneX

[HistoGeneX @HistoGeneX]

Our new partnership w/ @CaprionBioSci, fueled by a major investment from Arsenal Capital Partners, will allow us to provide a full suite of #biomarker development and immune monitoring services to #biopharmaceutical organizations worldwide. Read more at https://t.co/Yb7kpF50vr.

[HistoGeneX @HistoGeneX]

Thank you for a great year in 2017! We look forward to all that 2018 has to offer. Read about our year-end review: https://t.co/vJVxOlspkK

[HistoGeneX @HistoGeneX]

HistoGeneX partners with BluePrint 2 Initiative for review of digital slide reads https://t.co/mwsxH5vxha #WCLC2017 #LCSM

[HistoGeneX @HistoGeneX]

HistoGenex’s digital pathology technology plays key role in BluePrint 2 findings presented at IASLC. https://t.co/mwsxH5vxha #WCLC2017 #LCSM

[HistoGeneX @HistoGeneX]

Announced today at IASLC, read about HistoGeneX’s collaboration with BluePrint 2 Initiative. https://t.co/mwsxH5vxha #WCLC2017

[HistoGeneX @HistoGeneX]

Learn more at https://t.co/CGa8tu0bEf

[HistoGeneX @HistoGeneX]

Introducing our PanCK-CD8 assay: a validated, fully-automated IHC double stain assay that demarcates the position of CD8-expressing T cells.

[HistoGeneX @HistoGeneX]

Our new PanCK-CD8 assay: a fully-automated IHC double stain that clearly shows positions of CD8-expressing T cells. https://t.co/713PlTrZpw

[HistoGeneX @HistoGeneX]

One of our founders & Head Pathologist Mark Kockx was interviewed by @captodayonline on immunotherapy biomarkers. https://t.co/juSsyDaQa8

[HistoGeneX @HistoGeneX]

HistoGeneX is looking for an imaging scientist for our Antwerp location. See details on our careers page: https://t.co/HvuLQFcuAx

[HistoGeneX @HistoGeneX]

Want to improve the lives of patients facing cancer? We are looking for a quality assurance manager. More info: https://t.co/tNRa7UaF5b

[HistoGeneX @HistoGeneX]

Visit the HGX website for the full biomarker portfolio of validated & pipeline IHC assays. https://t.co/sx4NEXdFfU

[HistoGeneX @HistoGeneX]

Thanks to everyone who came out to our Naperville campus during #ASCO2916. We look forward to working with you in the future.

[HistoGeneX @HistoGeneX]

Good news! Just had an FDA inspection. Inspector found full "data integrity & no deviations apart from those already documented.”

[HistoGeneX @HistoGeneX]

Want to know more about HistoGenex? Subscribe to our newsletter: https://t.co/prJ12if3wj

[HistoGeneX @HistoGeneX]

Our multiple locations form one global lab - learn more about our quality assurance: https://t.co/XgfoWRpdNg

[HistoGeneX @HistoGeneX]

Our Naperville lab is open. Schedule your tour at https://t.co/SXGciuvryV - especially if you will be at #ASCO2016.